Global Dendritic Cell Cancer Vaccine Market Size By Product Type (Sipuleucel-T, CreaVax), By End-User (Pediatric, Adults), By Geographic Scope And Forecast
수지상세포 암 백신 시장 규모 및 전망
수지상세포 암 백신 시장 규모는 2024년에 24억 1,000만 달러로 평가되며, 2026년부터 2032년까지 CAGR 10.5%로 성장하여 2032년에는 51억 8,000만 달러에 달할 것으로 예상됩니다.
- 수지상세포는 암세포를 포함한 비정상적인 세포를 식별하고 제거하는 면역 체계를 돕습니다. 과학자들은 백신을 만들기 위해 암세포와 함께 수지상세포를 실험실에서 배양합니다. 우리의 면역 체계는 백신을 통해 악성 종양과 싸우도록 자극을 받습니다.
- 임상 II상 연구에서 수지상세포 면역은 종양에 침입하는 림프구의 수를 증가시켜 면역반응을 유도하고, 일부 환자에서 전체 생존기간을 개선할 수 있는 가능성을 보여주었습니다.
- 백신의 제조에는 β세포 단백질과 수지상세포로 알려진 환자 자신의 면역 세포가 사용됩니다. 이 백신 접종은 면역 체계에 베타 세포를 공격하도록 지시함으로써 베타 세포가 치유되고 혈당을 조절하기에 충분한 인슐린을 생산하도록 도와줄 수 있습니다.
- 전이성 전립선암, 신세포암, 신경교종, 흑색종 등 여러 종양이 수지상세포 암 백신의 임상시험 대상이 되고 있습니다.
수지상세포 암 백신 세계 시장 역학
세계 수지상세포 암 백신 시장을 형성하는 주요 시장 역학은 다음과 같습니다:
주요 시장 촉진요인
- 암 발병률 증가 : 매년 수백만 건의 새로운 암 사례가 보고되고 있으며, 암은 전 세계적으로 심각한 공중보건 문제입니다. 수지상세포 암 백신과 같은 새롭고 효율적인 치료법의 개발은 암 유병률 증가에 크게 기여하고 있습니다.
- 면역치료의 활용 확대 : 면역치료는 암세포와 싸우기 위해 면역체계를 자극하는 암 치료법입니다. 임상시험에서 가능성을 보인 면역요법 중 하나는 수지상세포 백신의 사용입니다. 수지상세포 암 백신에 대한 수요는 면역치료가 대중화됨에 따라 증가할 것으로 예상됩니다.
- 기술의 발전 : 기술의 발전으로 보다 정확하고 강력한 수지상세포 암 백신이 가능해졌습니다. 예를 들어, 과학자들은 수지상세포를 분리하고 자극하는 것뿐만 아니라 수지상세포 백신을 체내에 투여하는 새로운 접근법을 개발하고 있습니다.
- 연구개발비 증가 : 제약회사와 정부기관은 수지상세포 암 백신 연구 및 개발에 많은 투자를 하고 있습니다. 향후 몇 년 동안 이러한 투자로 인해 새롭고 개선된 예방접종이 개발될 것으로 예상됩니다.
주요 과제
- 제조의 복잡성 : 수지상세포 암 백신의 제조 절차는 환자 자신의 면역세포를 제거한 후 암을 표적으로 삼도록 실험실에서 변형시킨 후 면역세포를 환자에게 다시 주입하는 방식입니다. 백신 제조는 복잡하기 때문에 비용과 시간이 많이 소요됩니다.
- 제한된 효과 : 일부 연구에서 유망한 결과를 얻었지만, 덴드라이트 세포 암 백신 접종은 다양한 암종에 대해 신뢰할 수 없는 치료법임이 입증되고 있습니다. 이러한 백신 접종의 효과를 높이기 위해 연구자들은 제조 공정을 개선하기 위해 노력하고 있습니다.
- 기술의 발전기술의 발전으로 인해 수지상세포 암 백신 시장이 활성화되고 있습니다. 인공지능(AI)은 맞춤형 백신 접종과 이 치료법의 혜택을 가장 많이 받을 수 있는 환자를 식별하는 데 도움을 주고 있습니다. 또한, 유전체학은 종양의 최적 표적을 찾아내어 보다 효과적인 백신을 개발할 수 있도록 돕고 있으며, AI는 복잡한 제조 공정을 단순화하여 비용을 낮추고 접근성을 높일 수 있는 잠재력을 가지고 있습니다. 이러한 기술 개발의 융합은 강력한 맞춤형 수지상세포 암 백신 개발의 문을 열어주고 있습니다.
주요 동향
- 항원 탐색 : 유전체 해독은 종양 특이적 항원, 즉 면역학적 반응을 유도하는 화학제품을 발견하는 데 도움이 됩니다. 이러한 항원이 면역계를 자극하는 능력을 AI가 분석, 예측함으로써 보다 전문적인 백신 개발이 가능해집니다.
- 종양의 이질성 : 같은 암 환자라도 종양의 유전자 구성이 다르기 때문에 수지상세포 암 백신에 대한 수요가 증가하고 있습니다.
- 전문 지식의 결합 : 스타트업은 종종 최첨단 기술이나 특징적인 항원 타겟을 가지고 있는 반면, 기존 기업은 제조, 규제 절차, 임상시험에 대한 지식을 제공합니다. 이러한 기술을 결합하여 개별적인 한계를 극복하고 백신 개발을 가속화할 수 있습니다.
목차
제1장 수지상세포 암 백신 세계 시장 소개
제2장 주요 요약
제3장 VERIFIED MARKET RESEARCH 조사 방법
- 데이터 마이닝
- 검증
- 1차 자료
- 데이터 소스 리스트
제4장 수지상세포 암 백신 세계 시장 전망
- 개요
- 시장 역학
- Porter's Five Forces 모델
- 밸류체인 분석
제5장 수지상세포 암 백신 세계 시장 : 제품 유형
제6장 수지상세포 암 백신 세계 시장 : 최종사용자별
제7장 수지상세포 암 백신 세계 시장 : 지역별
제8장 수지상세포 암 백신 세계 시장 경쟁 구도
제9장 기업 개요
- GlaxoSmithKline plc
- 3M Company
- Activartis
- Batavia Bioservices
- Argos Therapeutics
- Sanpower Corporation
- Elios Therapeutics
- DanDrit Biotech
- DCPrime
- ImmunoCellular Therapeutics
제10장 주요 발전
- 제품 출시/개발
- 인수합병
- 사업 확대
- 파트너십과 제휴
제11장 부록
ksm
Dendritic Cell Cancer Vaccine Market Size And Forecast
Dendritic Cell Cancer Vaccine Market size was valued at USD 2.41 Billion in 2024 and is projected to reach USD 5.18 Billion by 2032, growing at a CAGR of 10.5% from 2026-2032.
- Dendritic cells aid the immune system in identifying and eliminating aberrant cells, including cancerous cells. Scientists cultivate dendritic cells alongside cancer cells in the lab in order to create the vaccine. Our immune system is then prompted to combat the malignancy by the vaccine.
- In phase II studies, it was demonstrated that dendritic cell immunization might boost the number of lymphocytes invading tumors, trigger an immune response, and improve overall survival for a subset of patients.
- A beta-cell protein and the patient's own immune cells, known as dendritic cells, are used to make the vaccine. The vaccination may help the beta-cells heal and produce adequate insulin to regulate blood sugar levels by instructing the immune system to attack on beta-cells.
- Multiple tumors, including metastatic prostate cancer, renal cell carcinoma, glioma, and melanoma, have been subjected to a clinical trial of the Dendritic Cell Cancer Vaccination.
Global Dendritic Cell Cancer Vaccine Market Dynamics
The key market dynamics that are shaping the global Dendritic Cell Cancer Vaccine Market include:
Key Market Drivers:
- Growing Cancer Prevalence: With millions of new cases reported each year, cancer is a serious public health concern on a global scale. The creation of novel and efficient therapies, such as dendritic cell cancer vaccines, is largely fueled by the rising prevalence of cancer.
- Expanding Use of Immunotherapy: Immunotherapy is a cancer treatment that stimulates the immune system to combat cancer cells. One type of immunotherapy that has shown potential in clinical trials is the use of dendritic cell vaccines. Dendritic cell cancer vaccine demand is predicted to increase as immunotherapy gains traction.
- Technology Advancements: More precise and potent dendritic cell cancer vaccines are now possible because due to technological advancements. For instance, scientists are creating novel approaches for delivering these vaccinations to the body as well as for isolating and stimulating dendritic cells.
- Rising R&D Expenditure: Drug companies and government agencies are making significant investments in the study and creation of vaccines against dendritic cell cancer. In the upcoming years, it is anticipated that this investment will result in the development of new and improved vaccinations.
Key Challenges:
- Complexity of Manufacturing: The procedure of creating dendrite cell cancer vaccines is removing a patient's own immune cells, modifying them in a laboratory to target the cancer, and then reintroducing the immune cells to the patient. The production of the vaccinations is costly and time-consuming due to their complication.
- Limited Efficacy: Although some research has yielded encouraging results, dendrite cell cancer vaccinations is proving an unreliable treatment for various cancer types. To increase the effectiveness of these vaccinations, researchers are trying to improve their manufacturing process.
- Technological Advancements: Dendritic Cell Cancer Vaccine Market is boosting thanks to the technological advancement. Personalized vaccinations and the identification of patients most likely to benefit from this therapy are being facilitated by artificial intelligence (AI). Furthermore, genomics is making it possible to identify the best tumor targets, which will result in vaccines that work better. AI is also simplifying the intricate manufacturing process, which could lower costs and improve accessibility. The convergence of technological developments is opening doors for the development of potent and customized dendritic cell cancer vaccines.
Key Trends:
- Antigen Discovery: Genomic sequencing aids in the discovery of tumor-specific antigens, or immunological response-inducing chemicals. The development of more specialized vaccinations will result from AI's analysis and prediction of these antigens' capacity to stimulate the immune system.
- Heterogeneity of Tumors: The difference in the genetic makeup of tumors even among patients with the same form of cancer is increasing the demand for dendritic cell cancer vaccine.
- Combination of Expertise: While new firms frequently have cutting-edge technologies or distinctive antigen targets, established players provide knowledge in manufacturing, regulatory procedures, and clinical trials. They can overcome individual limits and accelerate the development of vaccines by combining their skills.
Global Dendritic Cell Cancer Vaccine Market Regional Analysis
Here is a more detailed regional analysis of the global Dendritic Cell Cancer Vaccine Market:
North America:
- According to Verified Market Research analyst, North America is expected to hold a major share in the global Dendritic Cell Cancer Vaccine Market. North America has dominated the Dendritic Cell Cancer Vaccine Market mostly due to large-scale research studies funded by pharmaceutical companies and university research institutes, as well as an extraordinary surge in the prevalence of cancer cases.
- North American region spend a lot on healthcare, more money may be allocated to the study and creation of cutting-edge cancer treatments, such as dendrite cell cancer vaccinations.
- North America has the biggest market share due to increased awareness of cancer treatment and the availability of well-developed healthcare infrastructure and research facilities.
- In North America, there is a growing awareness of cancer and accessible treatment choices, which could lead to increasing patient interest in tailored therapies like DC vaccines.
Asia Pacific:
- Several countries in Asia-Pacific are actively sponsoring cancer immunotherapy research and development, including DC vaccines. This involves sponsoring programs and reducing regulatory procedures. Countries are developing reimbursement schemes for approved DC vaccines, making them more available to patients.
- The evolving healthcare system present encouraging prospects for market growth. Even though the market is still developing in comparison to North America and Europe, a number of domestic and foreign companies are actively engaged in research partnerships and clinical trials. This strong activity suggests that the Asia Pacific area has enormous potential to influence the direction of cancer treatment using dendritic cells.
- There is a growing need for new treatment alternatives due to the increased incidence of cancer cases in nations like China and India. A climate that is conducive to the uptake of dendritic cell vaccines is being created by rising public knowledge of immunotherapy and government backing for it.
Global Dendritic Cell Cancer Vaccine Market: Segmentation Analysis
The Global Dendritic Cell Cancer Vaccine Market is segmented on the basis of Product Type, End-User, and Geography.
Dendritic Cell Cancer Vaccine Market, By Product Type
Based on Product Type, the market is bifurcated into Sipuleucel-T and CreaVax. Sipuleucel-T has the greatest share of the market among the others. The treatment of metastatic prostate cancer in males with sipuleucel-T is clinically authorized. with growing in acceptance. Sipuleucel-T, formerly known as Provenge, is now the market leader for dendritic cell cancer vaccines. This is due to its unique status as the first cancer immunotherapy to receive FDA approval.
- Sipuleucel-T is a targeted treatment for men with metastatic castration-resistant prostate cancer who are asymptomatic or very symptomatic. Even though there are currently other dendritic cell vaccines being developed, Sipuleucel-T's established presence and demonstrated efficacy are probably going to help it maintain its market share going forward.
Dendritic Cell Cancer Vaccine Market, By End-User
Based on End-User, the market is bifurcated into Pediatric and Adults. In the market for cancer vaccines against dendritic cell carcinoma, the adult category is dominant. Numerous factors contribute to this supremacy. First off, adult cancer incidence rates are often higher than those in youngsters. Second, adult malignancies such as lung, breast, and prostate cancers are the focus of a sizable fraction of current clinical trials for dendritic cell vaccines.
- The purpose of these trials is to assess the novel medicines' safety and effectiveness in adult patients. Furthermore, well-known competitors in the market, such as the company that created Sipuleucel-T (Provenge), focus mostly on adult patients. Although there is ongoing research into pediatric dendritic cell vaccines, the adult segment currently holds a dominant position in the market due to its established therapeutic choices and state of research.
Key Players
The "Global Dendritic Cell Cancer Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline plc, 3M Company, Activartis, Batavia Bioservices, Argos Therapeutics, Sanpower Corporation, Elios Therapeutics, DanDrit Biotech, DCPrime, and ImmunoCellular Therapeutics.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
- Dendritic Cell Cancer Vaccine Market Recent Developments
- In September 2021, the development of immunotherapeutic techniques has allowed for the improvement of standard therapies' efficacy in the treatment of oncological disorders. Following the introduction of dendritic cell-based individualized therapeutic vaccines into clinical practice there was no significant advancement. The scope of use for dendritic cell (DC) vaccines has been expanded, and patient indicators for cancer have improved to a clearer understanding of dendritic cell biology and the adoption of novel techniques and agents for antigenic work. Furthermore, encouraging projections of DC vaccines application in broader clinical practice can be used due to their low toxicity in clinical trials.
- In June 2021, ASPAGNIITM was being used in dendritic cell (DC) based immunotherapy in cervical, ovarian cancer and will also be used in breast cancer. The process begins by extracting monocytes of white blood cell from the patient's blood. These monocytes are then transformed into dendritic cells which act as immune system messengers. The dendritic cells are equipped with a specific protein called ASPAGNIITM. This protein helps them recognize and target cancer cells expressing SPAG9. Finally, after being primed the dendritic cells are reintroduced into the body and there, they guide T cells to identify and destroy the cancer cells.
TABLE OF CONTENTS
1 INTRODUCTION OF GLOBAL DENDRITIC CELL CANCER VACCINE MARKET
- 1.1 Overview of the Market
- 1.2 Scope of Report
- 1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
- 3.1 Data Mining
- 3.2 Validation
- 3.3 Primary Interviews
- 3.4 List of Data Sources
4 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET OUTLOOK
- 4.1 Overview
- 4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
- 4.3 Porters Five Force Model
- 4.4 Value Chain Analysis
5 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, PRODUCT TYPE
- 5.1 Overview
- 5.2 Sipuleucel-T
- 5.3 CreaVax
6 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, END-USER
- 6.1 Overview
- 6.2 Pediatric
- 6.3 Adults
7 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, BY GEOGRAPHY
- 7.1 Overview
- 7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
- 7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
- 7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
- 7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East & Africa
8 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET COMPETITIVE LANDSCAPE
- 8.1 Overview
- 8.2 Company Market Ranking
- 8.3 Key Development Strategies
9 COMPANY PROFILES
- 9.1 GlaxoSmithKline plc
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
- 9.2 3M Company
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
- 9.3 Activartis
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
- 9.4 Batavia Bioservices
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
- 9.5 Argos Therapeutics
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
- 9.6 Sanpower Corporation
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
- 9.7 Elios Therapeutics
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
- 9.8 DanDrit Biotech
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
- 9.9 DCPrime
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
- 9.10 ImmunoCellular Therapeutics
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments
10 KEY DEVELOPMENTS
- 10.1 Product Launches/Developments
- 10.2 Mergers and Acquisitions
- 10.3 Business Expansions
- 10.4 Partnerships and Collaborations
11 Appendix
